Wanshi Shachong Xiaoji Pills Alleviate Functional Dyspepsia in Mice and Exhibit Lipid-Lowering Effects in a Hepatocyte Steatosis Model
Open Access
- 10 March 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (3) , 448
Abstract
Objective: To investigate the therapeutic effects and safety profile of Wanshi Shachong Xiaoji Pills (WSXPs) on a functional dyspepsia (FD) mouse model and to preliminarily explore its potential mechanism and impact on associated hepatic metabolism. Methods: An FD model was established in mice using L-arginine. Gastrointestinal motility was assessed by measuring gastric emptying and intestinal propulsion rates. Serum levels of gastrointestinal hormones (MTL, GAS, VIP, CCK) and gut microbiota composition were analyzed. A one-month repeated-dose toxicity study was conducted in normal mice to evaluate safety. The effects of WSXPs on lipid metabolism and inflammation were further examined in a hepatocyte steatosis model in vitro, and network pharmacology was employed to predict potential mechanisms. Results: WSXPs significantly alleviated FD symptoms by improving gastrointestinal motility, bidirectionally regulating gut hormone levels, and increasing the abundance of beneficial bacteria (Akkermansia muciniphila). Long-term administration showed no significant toxicity. In vitro, WSXPS reduced lipid accumulation and inflammation in hepatocytes. Network analysis identified the PI3K-Akt signaling pathway as a potentially central common target, providing a hypothesis for future mechanistic studies. Conclusions: WSXPs effectively improve FD symptoms, modulates gut microbiota, and exhibits potential benefits on hepatic lipid metabolism in vitro, possibly via the PI3K-Akt pathway. This hepatocyte-level finding, combined with its in vivo efficacy in FD, suggests a promising avenue for future research into its potential applications in metabolic-associated conditions. This study provides a scientific foundation for the further development and clinical application of WSXPs in treating FD.Keywords
Funding Information
- Huanggang City Demonstration and Pilot Project for the Inheritance, Innovation, and Development of Traditional Chinese Medicine (No. 42110022237T000000135)
- Special Fund for the Construction of the Modern Agricultural Industrial Technology System (CARS-21)
This publication has 33 references indexed in Scilit:
- Disorders of the gut‐brain interaction among European people with obesity: Prevalence and burden of compatible symptomsUnited European Gastroenterology Journal, 2025
- Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLDMetabolism, 2024
- Akkermansia muciniphila Improves Depressive-Like Symptoms by Modulating the Level of 5-HT Neurotransmitters in the Gut and Brain of MiceMolecular Neurobiology, 2023
- Targeting PI3K/AKT signaling pathway in obesityBiomedicine & Pharmacotherapy, 2023
- Recent findings in Akkermansia muciniphila-regulated metabolism and its role in intestinal diseasesClinical Nutrition, 2022
- The rich pharmacological activities of Magnolia officinalis and secondary effects based on significant intestinal contributionsJournal of Ethnopharmacology, 2021
- High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanismsChemico-Biological Interactions, 2020
- High-fat diet-derived free fatty acids impair the intestinal immune system and increase sensitivity to intestinal epithelial damageBiochemical and Biophysical Research Communications, 2020
- Phytochemicals, pharmacology, clinical application, patents, and products of Amomi fructusFood and Chemical Toxicology, 2018
- Fatty acids in a high-fat diet potentially induce gastric parietal-cell damage and metaplasia in miceJournal of Gastroenterology, 2016